A phase I, randomized, two-period, single-center study to assess the effect of CYP2D6 and CYP2C19 inhibitors on a single oral dose of AV650 [tolperisone] (300 mg) in healthy subjects
Phase of Trial: Phase I
Latest Information Update: 18 Sep 2007
At a glance
- Drugs Fluvoxamine; Paroxetine; Tolperisone
- Indications Anxiety disorders; Back pain; Depressive disorders; Irritable bowel syndrome; Obsessive-compulsive disorders; Social phobia
- Focus Pharmacokinetics
- Sponsors Avigen
- 18 Sep 2007 Status changed from recruiting to completed.
- 16 Apr 2007 New trial record.